Novo
- Top Stories
Novo Nordisk sues Hims & Hers over compounded obesity drugs
Novo Nordisk is taking legal action against online telehealth provider Hims & Hers for marketing cheaper, unapproved versions of the…
Read More » - Finance
Novo Nordisk A/S (NVO) Eyes Solidifying Its Market Position with Increased Advertising Spending
Novo Nordisk A/S (NYSE:NVO) has recently been highlighted as one of the 13 Best Extremely Profitable Stocks to Invest in…
Read More » - Money
Novo Nordisk debuts Wegovy weight-loss pill in the U.S.
Novo Nordisk, a Danish drugmaker, has introduced an oral pill form of their weight-loss drug Wegovy in the U.S. This…
Read More » - Top Stories
Wegovy-maker Novo Nordisk shares surge after GLP-1 pill approval
Novo Nordisk’s stock saw a significant increase of 6.9% on Tuesday following the approval of its groundbreaking GLP-1 pill by…
Read More » - Health
TrumpRx to offer discount weight loss drugs after Lilly, Novo deals
The Trump administration made a significant announcement on Thursday regarding a deal to expand access to popular obesity drugs produced…
Read More » - Money
Novo Nordisk says it’s cutting 9,000 workers amid increased competition for its obesity drug Wegovy
Novo Nordisk, a Danish pharmaceutical company known for its weight-loss drug Wegovy, announced on Wednesday that it will be cutting…
Read More » - Business
Wegovy-maker Novo Nordisk cutting 9000 jobs in restructuring
Novo Nordisk, the maker of Wegovy, announced a significant restructuring plan that will result in 9,000 job cuts, representing about…
Read More » - Health
Novo Nordisk, Regeneron, CDC shooting
The Centers for Disease Control and Prevention (CDC) in Atlanta recently faced a terrifying incident when a shooter attempted to…
Read More » - Health
Novo Nordisk’s obesity drug Wegovy cleared to treat live disease MASH
Novo Nordisk’s obesity drug Wegovy has received approval from U.S. regulators to treat metabolic dysfunction-associated steatohepatitis (MASH), a common liver…
Read More » - Money
Novo Nordisk shares fall 20% after company names new CEO and lowers its financial outlook
Novo Nordisk, a Danish pharmaceutical company, faced a significant setback on Tuesday as its shares plummeted by over 20%. The…
Read More »